TY - JOUR
T1 - Basic and clinical studies on cefetamet pivoxil
AU - Irabu, Yuei
AU - Fukuhara, Hiroshi
AU - Nakamura, Hiroaki
AU - Kaneshima, Hiroshi
AU - Shimoji, Katsuyoshi
AU - Kitsukawa, Keizo
AU - Shigeno, Yoshiteru
AU - Saito, Atsushi
AU - Taira, Shinko
AU - Nakasone, Isamu
AU - Kusano, Nobuchika
AU - Hokama, Seitetsu
PY - 1990
Y1 - 1990
N2 - We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin, with the following results. 1) Antimicrobial activity : the minimum inhibitory concentrations (MICs) of cefetamet (CEMT) against 338 clinically isolated strains were determined and compared with those of cefteram, cefixime, cefaclor, cefotiam, ampicillin, using a Dynatech MIC-2000 system. CEMT had wide-spectrum antimicrobial activity against these isolated strains, except Pseudomonas aeruginosa, methicillin sensitive Staphylococcus aureus and methicillin resistant S. aureus. 2) Clinical efficacy : CEMT-PI at 500 or 1,000 mg/day was given to 2 patients with bacterial pneumonia, 2 with bacterial pneumonia complicated with chronic bronchitis, 5 with chronic bronchitis and 1 with diffuse panbronchiolitis for 4-14 days. Clinical response was excellent in 2 patients, good in 6, fair in 1 and poor in 1, and the overall clinical efficacy was 80%. 3) Bacteriological efficacy : one strain of Haemophilus influenzae was eradicated, one strain of Klebsiella pneumoniae changed to Proteus vulgaris, and one strain of Streptococcus pneumoniae persisted. 4) Safety : no side effects and altered laboratory findings were observed.
AB - We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin, with the following results. 1) Antimicrobial activity : the minimum inhibitory concentrations (MICs) of cefetamet (CEMT) against 338 clinically isolated strains were determined and compared with those of cefteram, cefixime, cefaclor, cefotiam, ampicillin, using a Dynatech MIC-2000 system. CEMT had wide-spectrum antimicrobial activity against these isolated strains, except Pseudomonas aeruginosa, methicillin sensitive Staphylococcus aureus and methicillin resistant S. aureus. 2) Clinical efficacy : CEMT-PI at 500 or 1,000 mg/day was given to 2 patients with bacterial pneumonia, 2 with bacterial pneumonia complicated with chronic bronchitis, 5 with chronic bronchitis and 1 with diffuse panbronchiolitis for 4-14 days. Clinical response was excellent in 2 patients, good in 6, fair in 1 and poor in 1, and the overall clinical efficacy was 80%. 3) Bacteriological efficacy : one strain of Haemophilus influenzae was eradicated, one strain of Klebsiella pneumoniae changed to Proteus vulgaris, and one strain of Streptococcus pneumoniae persisted. 4) Safety : no side effects and altered laboratory findings were observed.
KW - CEMT-PI
KW - Cefetamet pivoxil
UR - http://www.scopus.com/inward/record.url?scp=0025641121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025641121&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.38.Supplement1_193
DO - 10.11250/chemotherapy1953.38.Supplement1_193
M3 - Article
AN - SCOPUS:0025641121
VL - 38
SP - 193
EP - 197
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
ER -
